Loading
A phase 3 trial of Capecitabine, Eribulin and Gemcitabine in HER2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06957886 by Sichuan Baili Pharmaceutical Co., Ltd., with 566 participants planned, started 2025-05-15 and due to reach its primary completion in 2027-05. Interventions recorded: BL-M07D1 and Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
Shares Eribulin, SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, HER2-positive breast cancer and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.